Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Sell
19
PHBBF Quote, Financials, Valuation and Earnings
Last price:
$1.93
Seasonality move
:
0%
Day range:
$1.93 - $1.93
52-week range:
$1.93 - $1.93
Dividend yield:
1.44%
P/E ratio:
16.26x
P/S ratio:
1.83x
P/B ratio:
1.67x
Volume:
--
Avg. volume:
--
1-year change:
--
Market cap:
$3.4B
Revenue:
$1.7B
EPS (TTM):
$0.12
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Pharmaron Beijing Co., Ltd. has -- downside to fair value with a price target of -- per share.
PHBBF vs. S&P 500
-
Over the past 5 trading days, Pharmaron Beijing Co., Ltd. has overperformed the S&P 500 by 0.05% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Pharmaron Beijing Co., Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pharmaron Beijing Co., Ltd. has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Pharmaron Beijing Co., Ltd. reported revenues of $501.3M.
Earnings Growth
-
Pharmaron Beijing Co., Ltd. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Pharmaron Beijing Co., Ltd. reported earnings per share of $0.03.
Enterprise value:
4.1B
EV / Invested capital:
1.35x
Price / LTM sales:
1.83x
EV / EBIT:
14.88x
EV / Revenue:
2.19x
PEG ratio (5yr expected):
--
EV / Free cash flow:
100.30x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
9.34x
Gross Profit (TTM):
$623.2M
Return On Assets:
5.7%
Net Income Margin (TTM):
10.49%
Return On Equity:
9.62%
Return On Invested Capital:
6.8%
Operating Margin:
14.35%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.6B | $1.6B | $1.9B | $444.6M | $501.3M | |
| Gross Profit | $563.5M | $539.9M | $623.2M | $152M | $168.7M | |
| Operating Income | $240M | $214.2M | $274.8M | $68.6M | $71.9M | |
| EBITDA | $375.9M | -- | -- | $109.6M | -- | |
| Diluted EPS | $0.12 | $0.14 | $0.12 | $0.02 | $0.03 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.3B | $906.8M | $988.5M | $1B | $1.1B | |
| Total Assets | $2.7B | $2.8B | $3.1B | $3.4B | $3.6B | |
| Current Liabilities | $394.9M | $514.2M | $508.3M | $592.4M | $729.6M | |
| Total Liabilities | $1.2B | $1.3B | $1.4B | $1.4B | $1.5B | |
| Total Equity | $1.5B | $1.5B | $1.7B | $2B | $2.1B | |
| Total Debt | $730.3M | $729.9M | $791M | $740.4M | $723.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | $332.8M | -- | $110.6M | $147M | |
| Cash From Investing | -- | -$184.3M | -- | -$109.9M | -$144.4M | |
| Cash From Financing | -- | -$172.2M | -- | -$36.8M | -$17.6M | |
| Free Cash Flow | -- | $39.6M | -- | $30.3M | $41.1M | |
PHBBF
Sector
Market Cap
$3.4B
$28.5M
Price % of 52-Week High
100%
51.43%
Dividend Yield
1.44%
0%
Shareholder Yield
0.86%
-1.33%
1-Year Price Total Return
--
-21.18%
Beta (5-Year)
--
0.519
Dividend yield:
1.44%
Annualized payout:
$0.03
Payout ratio:
-4.8%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.93
200-day SMA
Sell
Level
$1.93
Bollinger Bands (100)
Sell
Level
1.93 - 1.93
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$1.93
Relative Strength Index (RSI14)
Sell
Level
0.00
ADX Line
Neutral
Level
41.08
Williams %R
Buy
Level
0
50-day SMA
Sell
Level
$1.93
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Neutral
Level
1.2K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8904)
Buy
CA Score
(Annual)
Level (0.1176)
Buy
Beneish M-Score
(Annual)
Level (-2.4343)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-1.4616)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pharmaron Beijing Co., Ltd. engages in the provision of full-process integrated drug research, development, and production services from drug discovery to drug development. It provides laboratory, CMC, macromolecules and cell & gene therapy, and clinical research services. The company was founded by Bo Liang Lou, Xiao Qiang Lou and Bei Zheng on July 1, 2004 and is headquartered in Beijing, China.
Stock Forecast FAQ
In the current month, PHBBF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PHBBF average analyst price target in the past 3 months is --.
-
Where Will Pharmaron Beijing Co., Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pharmaron Beijing Co., Ltd. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Pharmaron Beijing Co., Ltd.?
Analysts are divided on their view about Pharmaron Beijing Co., Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pharmaron Beijing Co., Ltd. is a Sell and believe this share price will rise from its current level to --.
-
What Is Pharmaron Beijing Co., Ltd.'s Price Target?
The price target for Pharmaron Beijing Co., Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PHBBF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pharmaron Beijing Co., Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of PHBBF?
You can purchase shares of Pharmaron Beijing Co., Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pharmaron Beijing Co., Ltd. shares.
-
What Is The Pharmaron Beijing Co., Ltd. Share Price Today?
Pharmaron Beijing Co., Ltd. was last trading at $1.93 per share. This represents the most recent stock quote for Pharmaron Beijing Co., Ltd.. Yesterday, Pharmaron Beijing Co., Ltd. closed at $1.93 per share.
-
How To Buy Pharmaron Beijing Co., Ltd. Stock Online?
In order to purchase Pharmaron Beijing Co., Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PHBBF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PHBBF
Sector
P/E ratio
16.26x
23.66x
PEG ratio
--
-0.01x
P/B ratio
1.67x
1.82x
Price / LTM sales
1.83x
1.61x
Growth Metrics
PHBBF
Sector
Revenue growth
12.76%
4.8%
Earnings growth
44.4%
11.11%
Revenue (5-year growth)
25.69%
6.45%
Earnings forecast
--
-$0.20
Profitability
PHBBF
Sector
Profitability FY 2024
$576.5M
$3.6M
Return on invested capital
6.8%
-31.15%
Return on assets
5.7%
-27.72%
Return on equity
9.62%
-36.72%
Earnings Date
Last Earnings Date
Oct
28
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Jan
27
Balance Sheet
PHBBF
Sector
Total cash
$320.2M
$27M
Short term investments
--
$25.7M
Total assets
$3.3B
$79.7M
Long term debt
$723.4M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
67
GPCR alert for Dec 9
Structure Therapeutics, Inc. [GPCR] is down 2.06% over the past day.
Buy
62
SMX alert for Dec 9
SMX (Security Matters) Plc [SMX] is up 0.21% over the past day.
Buy
90
KYMR alert for Dec 9
Kymera Therapeutics, Inc. [KYMR] is down 7.99% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
